Morgan Stanley lowered the firm’s price target on Compass Pathways (CMPS) to $16 from $18 and keeps an Overweight rating on the shares after the company reported Q4 results. 26-week Part B data from the COMP006 study is expected in early Q3 and management anticipates NDA submission in Q4, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways reports Q4 EPS ($1.00) vs. (63c) last year
- Compass Pathways sees cash runway into 2028
- Neuronetics price target lowered to $3 from $7 at Canaccord
- COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating
- 3 Best Stocks to Buy in Today’s Volatile Market, 3/4/2026, According to Top Analysts